Scalp cooling therapy for chemotherapy-induced hair loss in patients with breast or gynecological cancers-an Asian tertiary institution experience.

Humans Female Alopecia / chemically induced Breast Neoplasms / drug therapy Middle Aged Hypothermia, Induced / methods Genital Neoplasms, Female / drug therapy Adult Aged Scalp Tertiary Care Centers Antineoplastic Agents / adverse effects Bridged-Ring Compounds / adverse effects Anthracyclines / adverse effects Taxoids / adverse effects

Asian population Breast cancer Chemotherapy-induced alopecia Gynaecological cancer Scalp cooling therapy

Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

ISSN: 1433-7339

Titre abrégé: Support Care Cancer

Pays: Germany

ID NLM: 9302957

Informations de publication

Date de publication:
01 Nov 2024

Historique:

received: 19 02 2024

accepted: 13 10 2024

medline: 1 11 2024

pubmed: 1 11 2024

entrez: 1 11 2024

Statut: epublish

Résumé

Scalp cooling therapy (SCT) improves chemotherapy-induced alopecia (CIA), but there are few published data about its efficacy in an Asian-predominant population. We report our tertiary institution experience of SCT in patients with breast or gynaecological cancers undergoing chemotherapy. The Paxman scalp cooling system was employed for eligible women with breast or gynaecological cancers receiving anthracycline or taxane-based chemotherapy. Only patients with Grade (G) 0-1 alopecia by common terminology criteria for adverse events (CTCAE) version 4.0 were eligible initially, but patients with G2 alopecia were later included in the study. SCT was performed at each chemotherapy cycle, commencing 30 min prior to and continuing up to 90 min after completion of the drug infusion. Patients were assessed at the start and end of each session for hair preservation (defined as G0-2 alopecia) and comfort level of SCT (rated on a 5-point visual scale). The primary end point was success of hair preservation or hair regrowth after completion of all cycles of chemotherapy. Eighty-three patients were enrolled over a period of 18 months from December 2017 to October 2019, with a total of 510 scalp cooling cycles performed. 94.0% (n = 78) of patients reported a comfort score of 3 and above, indicating that the procedure was comfortable, upon a 5-point visual scale. Patients receiving weekly paclitaxel had highest success in hair preservation at 76.7% (23/30 patients), with a lower rate of hair preservation observed for the 3 weekly paclitaxel regimen (50%, 2/4 patients). In contrast, only 1 patient (5.3%, 1/19 patients) who underwent chemotherapy with anthracycline and cyclophosphamide achieved hair preservation. SCT is well tolerated in an Asian-predominant population. Among women with breast or gynaecological cancers receiving taxane and/or anthracycline based chemotherapy, those who underwent SCT were about 50% more likely to achieve hair preservation or hair regrowth, as compared to historical controls.

Identifiants

DOI: 10.1007/s00520-024-08940-2 PMID: 39482416

pubmed: 39482416

doi: 10.1007/s00520-024-08940-2

pii: 10.1007/s00520-024-08940-2

doi:

Substances chimiques

Antineoplastic Agents 0

taxane 1605-68-1

Bridged-Ring Compounds 0

Anthracyclines 0

Taxoids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

762

Informations de copyright

Références

Koszalinski RS, Williams C (2012) Embodying identity in chemotherapy-induced alopecia. Perspect Psychiatr Care 48(2):116–121

doi: 10.1111/j.1744-6163.2011.00314.x pubmed: 22458725

Rosman S (2004) Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns 52(3):333–339

doi: 10.1016/S0738-3991(03)00040-5 pubmed: 14998604

Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D (2004) Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer 12(8):1

doi: 10.1007/s00520-003-0562-5

Rossi A, Fortuna MC, Caro G, Pranteda G, Garelli V, Pompili U, Carlesimo M (2017) Chemotherapy-induced alopecia management: clinical experience and practical advice. J Cosmet Dermatol 16(4):537–541

doi: 10.1111/jocd.12308 pubmed: 28150447 pmcid: 5540831

Rossi A, Caro G, Fortuna MC, Pigliacelli F, D’Arino A, Carlesimo M (2020) Prevention and treatment of chemotherapy-induced alopecia. Dermatol Pract Conceptual 10(3):e2020074

doi: 10.5826/dpc.1003a74

Paus R, Haslam IS, Sharov AA, Botchkarev VA (2013) Pathobiology of chemotherapy-induced hair loss. Lancet Oncol 14(2):e50–e59

doi: 10.1016/S1470-2045(12)70553-3 pubmed: 23369683

A, Cuevas MA, Langhi M, Romero Acuña L, Romero Acuña J, Amato S, Barbieri M et al (1994) Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Ann Oncol. 5(8):769–70

Glaser DA, Hossain P, Perkins W et al (2015) Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 172(5):1384–1394

doi: 10.1111/bjd.13443 pubmed: 25296533 pmcid: 4832276

Al-Tameemi W, Dunnill C, Hussain O et al (2014) Use of in vitro human keratinocyte models to study the effect of cooling on chemotherapy drug-induced cytotoxicity. Toxicol In Vitro 28:1366–1376

doi: 10.1016/j.tiv.2014.07.011 pubmed: 25091624

Janssen FP, Rajan V, Steenbergen W et al (2007) The relationship between local scalp skin temperature and cutaneous perfusion during scalp cooling. Physiol Meas 28:829–839

doi: 10.1088/0967-3334/28/8/006 pubmed: 17664675

Dunnill et al (2020) Cooling-mediated protection from chemotherapy drug-induced cytotoxicity in human keratinocytes by inhibition of cellular drug uptake. PLoS One 15(10):e0240454

Vichi P, Robison S, Tritton TR (1989) Temperature dependence of adriamycin-induced DNA damage in L1210 cells. Cancer Res 49:5575–5580

pubmed: 2551489

Nangia J, Wang T, Osborne C et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP Randomized Clinical Trial. JAMA 317(6):596–605

doi: 10.1001/jama.2016.20939 pubmed: 28196254

Rugo HS, Klein P, Melin SA et al (2017) Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 317(6):606–614

doi: 10.1001/jama.2016.21038 pubmed: 28196257 pmcid: 5639721

Bajpai J, Kagwade S, Chandrasekharan A, Dandekar S, Kanan S, Kembhavi Y, Ghosh J, Banavali SD, Gupta S (2020) Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia. Breast 49:187–193

doi: 10.1016/j.breast.2019.12.004 pubmed: 31865282

Shin H, Jo SJ, Kim DH, Kwon O, Myung SK (2015) Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer 136(5):E442

doi: 10.1002/ijc.29115 pubmed: 25081068

van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504

doi: 10.3109/0284186X.2012.658966 pubmed: 22304489

Mitric C, How B, Matanes E et al (2021) Scalp cooling for reducing alopecia in gynecology oncology patients treated with dose-dense chemotherapy: a pilot project. Gynecol Oncol Rep 37:100842

doi: 10.1016/j.gore.2021.100842 pubmed: 34401437 pmcid: 8355950

Friedrichs K, Carstensen MH (2014) Successful reduction of alopecia induced by anthracycline and taxane containing adjuvant chemotherapy in breast cancer—clinical evaluation of sensor-controlled scalp cooling. Springerplus 3:500

doi: 10.1186/2193-1801-3-500 pubmed: 25279292 pmcid: 4165861

Spaeth D, Luporsi E, Weber B et al (2008) Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): a prospective study of 911 patients (pts). J Clin Oncol 26(15S):9564

doi: 10.1200/jco.2008.26.15_suppl.9564

Vasconcelos I, Wiesske A, Schoenegg W (2018) Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline/taxane-based chemotherapy. Breast 40(1):3

Giarratano T, Frezzini S, Zanocco M, Giorgi CA, Mioranza E, Miglietta F et al (2019) Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: a prospective study. Breast J 26(7):1296–1301

doi: 10.1111/tbj.13711 pubmed: 31837103

Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME (2018) Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 167(1):117–122

doi: 10.1007/s10549-017-4506-z pubmed: 28921303

Villarreal-Garza C, Mesa-Chavez F, Garza-Ledezma MRA, Peña-Curiel O, Martinez-Cannon BA, Canavati-Marcos M, Cardona-Huerta S (2021) Impact of chemotherapy regimen and sequence on the effectiveness of scalp cooling for alopecia prevention. Breast Cancer Res Treat 185(2):453–458

doi: 10.1007/s10549-020-05968-w pubmed: 33125621

Kinoshita T, Nakayama T, Fukuma E, Inokuchi M, Ishiguro H, Ogo E, Kikuchi M, Jinno H, Yamazaki N, Toi M (2019) Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast cancer patients: The HOPE Study. Front Oncol 6(9):733

doi: 10.3389/fonc.2019.00733

Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18(7):885–891

doi: 10.1634/theoncologist.2012-0332 pubmed: 23650021 pmcid: 3720643

Leerunyakul K, Suchonwanit P (2020) Asian hair: a review of structures, properties, and distinctive disorders. Clin Cosmet Investig Dermatol 24(13):309–318

doi: 10.2147/CCID.S247390

Chan J, Adderley H, Alameddine M, Armstrong A, Arundell D, Fox R, Harries M, Lim J, Salih Z, Tetlow C, Wong H, Thorp N (2021) Permanent hair loss associated with taxane chemotherapy use in breast cancer: a retrospective survey at two tertiary UK cancer centres. Eur J Cancer Care (Engl) 30(3):e13395

doi: 10.1111/ecc.13395 pubmed: 33350015

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J (2019) Permanent chemotherapy-induced alopecia in patients with breast cancer: a 3-year prospective cohort study. Oncologist 24(3):414–420

doi: 10.1634/theoncologist.2018-0184 pubmed: 30120165

Danbee K, Juhee C, Di Z, Jeonghyun K, Nayeon K, Hoyoung K, Sooyeon K, Ji-Yeon K, Yeon Hee P, Young HI, Eliseo G, Jin SA (2024) Scalp cooling in preventing persistent chemotherapy-induced alopecia: a randomized controlled trial. J Clin Oncol 42(26):3115–3122

doi: 10.1200/JCO.23.02374